On July 18, 2022, the first UK participant in our open-label Phase 2 study of MDMA-assisted therapy for PTSD was screened by the research team at the Institute of Psychiatry, Psychology & Neuroscience …
The MAPS Europe team is delighted to announce that screening of participants for our open-label Phase 2 study of MDMA-assisted therapy for PTSD has begun at the Charité – Universitätsmedizin Berlin …
MAPS Europe is delighted to announce that on March 23, 2022, the first site in the United Kingdom was activated and will begin screening patients in our open-label Phase 2 study of MDMA-assisted therapy …
MAPS Europe is delighted to announce that as of March 7, 2022, recruitment of patients into the MP18 study began at the Department of Psychiatry and Neurosciences in the Charité – Universitätsmedizin …
As of January 2022, sites in The Netherlands and the Czech Republic are continuing to enroll patients for our Phase 2 study, an optional fMRI sub-study assessing changes in brain activity in subjects with …
FOR IMMEDIATE RELEASE MDMA as an adjunct to therapy for PTSD is the forty-first treatment to receive the Innovation Passport since its inception in January 2021 The designation is intended to accelerate …
As of January 2022, sites in The Netherlands and the Czech Republic are continuing to enroll patients for our Phase 2 study, an optional fMRI sub-study assessing changes in brain activity in subjects with …
We are very excited to share updates for the open-label lead-in study of MDMA-assisted therapy for PTSD in Europe, including news about enrollment progress and first MDMA-assisted therapy session! Data …
Taking place in the United Kingdom, Germany, Portugal, Norway, the Czech Republic, and the Netherlands, this open-label Phase 2 study of MDMA-assisted therapy for PTSD will serve as the lead-in to the …
Taking place in the United Kingdom, Germany, Portugal, Norway, the Czech Republic, and the Netherlands, this open-label Phase 2 study of MDMA-assisted therapy for PTSD will serve as the lead-in to the …
Taking place in the United Kingdom, Germany, Portugal, Norway, the Czech Republic, and the Netherlands, this open-label Phase 2 study of MDMA-assisted therapy for PTSD will serve as the lead-in to the …
Taking place in the United Kingdom, Germany, Portugal, Norway, the Czech Republic, and the Netherlands, this open-label Phase 2 study of MDMA-assisted psychotherapy for PTSD will serve as the lead-in to …
